The Role of Radiotherapy in the Treatment of Early Stage Ocular Marginal Zone Lymphoma

1. Abstract
To evaluate the benefit of radiotherapy, compared with other treatment in ocular marginal zone lymphoma, retrospectively we analyzed our experience, with the end-points: efficacy, measured for complete response, Progression-Free Survival (PFS) and Overall Survival (OS).
Patients pathological confirmed as marginal zone, limited to ocular site, in early stage (I), without previous treatments, > 18 years, were included. From August 1988 to December 2015, 301 patients were treated with Radiotherapy (RT), RT + chemotherapy, and RT + rituximab. The median follow-up was 20.3 (range 6 to 34) years. Complete response, PFS and OS did not show any statistical difference Acute and late toxicities were well tolerated, the most common were formation of cataracts, associated with more dose of RT, and did not employed, who did not protect with lens shielding. Late toxicities as acute leukemia and second neoplasms did not were observed.